The Kalshi promo code GOAL can be used to claim $10 in sign up bonuses. This can be used kickstart new Kalshi users trading ...

HGS (listed on BSE & NSE), a leading provider of digital experience, business process management (BPM), and digital media services, today announced the launch of AMLens, a next-generation, AI-powered ...

It seems to me that correcting an incorrect Date of Birth for a director or PSC on the Companies House record is a bit of a pain. Is it simplest to ...

The configuration.yaml file is a set of instructions commonly located under the config directory on your Home Assistant server. The YAML extension refers to the type of formatting used within the file ...

Amphista Therapeutics has reported preclinical leukemia data on its protein degrader, positioning the Big Pharma-partnered biotech to target a 2026 start date for a phase 1 clinical trial. The data, ...

In a new trial, patients newly diagnosed with acute myeloid leukemia (AML) fared significantly better with a combined regimen of azacitidine and venetoclax compared with conventional induction ...

ORLANDO, Fla. — A new analysis of three decades of clinical trial data confirms that Black patients with acute myeloid leukemia (AML) have worse survival outcomes than White patients. However, ...

A new generation of targeted treatments and gentler chemotherapy options for older adults with a new diagnosis of acute myeloid leukemia (AML) is driving better survival and cure rates. Led by Mikkael ...

A new generation of targeted treatments and gentler chemotherapy options for older adults with a new diagnosis of acute myeloid leukemia (AML) is driving better survival and cure rates. Led by Mikkael ...

The OCC on Monday released new Bank Secrecy Act guidance that simplifies anti-money laundering examination procedures for community banks, a significant tailoring effort they say is aimed at reducing ...

Kyowa Kirin’s big bet on Kura Oncology has paid off in short order, delivering an FDA approval for a medicine to treat a subset of patients with acute myeloid leukemia. On Thursday, the FDA signed off ...

Revumenib received FDA approval for relapsed or refractory mNPM1 AML, supported by AUGMENT-101 trial data showing a 26% complete remission rate. The AUGMENT-101 trial demonstrated a consistent safety ...